For Research Use Only

Recombinant Human CD40L/CD154 protein (rFc Tag)



Catalog Number: Eg3501

Basic Information

Species: Human

Purity: >90 %, SDS-PAGE

Tag: rFc Tag

Technical Specifications

Purity: >90 %, SDS-PAGE

Endotoxin Level:

<1.0 EU/ μ g protein, LAL method

HEK293-derived Human CD40L/CD154 protein Met113-Leu261 (Accession# P29965) with a rabbit IgG Fc tag at the N-terminus.

GeneID:

959

Accession: P29965

Predicted Molecular Mass:

43.4 kDa

Lyophilized from sterile PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.

Biological Activity

Not tested

Storage and Shipping

It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.

Until expiry date, -20°C to -80°C as lyophilized proteins.

3 months, -20℃ to -80℃ under sterile conditions after reconstitution.

The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Reconstitution

Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.

Background

The CD40 ligand (CD40L), also known as TRAP or CD154, is a member of the TNF superfamily of ligands. CD40L The CD40 ligand (CD40L), also known as TRAP or CD154, is a member of the TNF superfamily of ligands. CD40 is primarily expressed on activated CD4+ T cells and on a small proportion of CD8+ T cells and platelets. It binds to CD40 on antigen-presenting cells (APC), which leads to many effects depending on the target cell type. It has been suggested that CD40/CD40L interactions regulate oxidative stress and affect various signaling pathways in both the immunological and the cardiovascular systems. The CD40/CD40L system is also involved in tumorigenesis. Its expression is tightly regulated, and abnormal levels of CD40L are associated with the pathogenesis of atheromatous plaque destabilization and thrombotic events. Multiple mutations in CD40LG gene have been identified that are associated with hyper-IgM immunodeficiency syndrome type 1.

References

- 1. Elgueta R. et al. (2009). Immunol Rev. 229(1):152-172. 2. Rizvi M. et al. (2008). Trends Mol Med. 14(12):530-538. 3. Michel N A. et al. (2017). Front Cardiovasc Med. 4:40.

Synonyms

CD154, CD40L; CD154, CD40LG, CD 154, CD 40L

Selected Validation Data